|
|
Blood, 1 June 2006, Vol. 107, No. 11, pp. 4214-4222.
Prepublished online as a Blood First Edition Paper on February 16, 2006; DOI 10.1182/blood-2005-08-3526.
 Previous Article | Table of Contents | Next Article 
REVIEW ARTICLES
Molecular basis of the diagnosis and treatment of polycythemia vera and essential thrombocythemia
Andrew I. Schafer
From the Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia.
Recent insights into the molecular mechanisms of polycythemia vera (PV) and essential thrombocythemia (ET) are challenging the traditional diagnostic classification of these myeloproliferative disorders (MPDs). Clonality analysis using X-chromosome inactivation patterns has revealed apparent heterogeneity among the MPDs. The recently discovered single somatic activating point mutation in the JAK2 gene (JAK2-V617F) is found in the great majority of patients with PV, but also in many patients with phenotypically classified ET and other MPDs. In contrast to the acquired MPDs, mutations of the erythropoietin receptor and thrombopoietin receptor have been identified in familial forms of nonclonal erythrocytosis and thrombocytosis, respectively. The mechanisms of major clinical complications of PV and ET remain poorly understood. Quantitative or qualitative abnormalities of red cells and platelets do not provide clear explanations for the thrombotic and bleeding tendency in these MPDs, suggesting the need for entirely new lines of research in this area. Recently reported randomized clinical trials have demonstrated the efficacy and safety of low-dose aspirin in PV, and an excess rate of arterial thrombosis, major bleeding, and myelofibrotic transformation, but decreased venous thrombosis, in patients with ET treated with anagrelide plus aspirin compared to hydroxyurea plus aspirin.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
F. Passamonti, M. L. Randi, E. Rumi, E. Pungolino, C. Elena, D. Pietra, M. Scapin, L. Arcaini, F. Tezza, R. Moratti, et al.
Increased risk of pregnancy complications in patients with essential thrombocythemia carrying the JAK2 (617V>F) mutation
Blood,
July 15, 2007;
110(2):
485 - 489.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Finazzi and T. Barbui
How I treat patients with polycythemia vera
Blood,
June 15, 2007;
109(12):
5104 - 5111.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Diwan, A. G. Koesters, A. M. Odley, S. Pushkaran, C. P. Baines, B. T. Spike, D. Daria, A. G. Jegga, H. Geiger, B. J. Aronow, et al.
Unrestrained erythroblast development in Nix-/- mice reveals a mechanism for apoptotic modulation of erythropoiesis
PNAS,
April 17, 2007;
104(16):
6794 - 6799.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Hammond, K. Shaw, B. Carnley, S. P'ng, I. James, and R. Herrmann
Quantitative Determination of JAK2 V617F by TaqMan: An Absolute Measure of Averaged Copies per Cell That May Be Associated with the Different Types of Myeloproliferative Disorders
J. Mol. Diagn.,
April 1, 2007;
9(2):
242 - 248.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Carobbio, G. Finazzi, V. Guerini, O. Spinelli, F. Delaini, R. Marchioli, G. Borrelli, A. Rambaldi, and T. Barbui
Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors, and Jak2 mutation status
Blood,
March 15, 2007;
109(6):
2310 - 2313.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. M. Vannucchi and T. Barbui
Thrombocytosis and Thrombosis
Hematology,
January 1, 2007;
2007(1):
363 - 370.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Barbui and G. Finazzi
Myeloproliferative Disease in Pregnancy and Other Management Issues
Hematology,
January 1, 2006;
2006(1):
246 - 252.
[Abstract]
[Full Text]
[PDF]
|
|
|
| |
